Hypoxia-Activated Prodrug Platform
Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Prostate Cancer, Head and Neck Squamous Cell Carcinoma
Pre-clinicalActive
Key Facts
Indication
Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Prostate Cancer, Head and Neck Squamous Cell Carcinoma
Phase
Pre-clinical
Status
Active
Company
About Convert Pharmaceuticals
Convert Pharmaceuticals is a pioneering, platform-based biotech company leveraging tumor hypoxia to develop targeted cancer therapies. Its core technology involves designing prodrugs activated specifically in the low-oxygen tumor microenvironment, aiming to improve potency and reduce systemic toxicity. The company is advancing its pipeline with support from non-dilutive grants like the EIC Accelerator and is actively seeking Series A investment. Its approach is validated by recent academic research, positioning it to address treatment-resistant cancers.
View full company profile